HOXB13 and ductal breast carcinoma in situ: This apparent discrepancy with our results can be ascribed to the different methods used for the analysis (methylation-specific PCR versus our genome-wide DNA methylation profiling), the different specimens examined in the two studies (invasive-stage breast carcinomas versus DCIS), and the different location of the CpG islands on the HOXB13 gene (promoter versus an intragenic CpG island, target number 37).